Current substance use in patients with gastric cancer in Southern Iran.

BACKGROUND: Psychiatric disorders may affect patients suffering from cancer and substance use disorders. OBJECTIVE: This study was undertaken to evaluate the prevalence of tobacco and opioid use in patients with gastric cancer in Shiraz, Fars Province and Southern Iran. MATERIALS AND METHODS: In a hospital survey of 177 gastric cancer patients aged 24 years and more, a semistructured-interview was performed based on SDM-IV criteria during the year 2003. RESULTS: The mean age of the patients was 58.13 (SD = 14.03) years. Among the subjects, 50.9% (90) were tobacco dependent (61.5% men and 29.4% women, P < 0.001), while 10 (5.7%) were opioid-dependent (7.3% men and 1.9% women, P = 0.16). Tobacco and opioid-dependency were not significantly related to age groups, economical or occupational status. Mean ages of tobacco and opioid-dependants were not significantly different from nondependants. CONCLUSIONS: Tobacco and opioid dependency were common problems among gastric cancer patients. This report provides useful information for health planning. Men were at greater risk than women. Treatment programs should focus on all age-groups, all occupations and all income-levels.

Anti-HBc & HBV-DNA detection in blood donors negative for hepatitis B virus surface antigen in reducing risk of transfusion associated HBV infection.

BACKGROUND & OBJECTIVE: Though sensitive screening assays for detection of hepatitis B virus surface antigen (HBsAg) are available, occasional cases of post-transfusion hepatitis B virus infection (PTH) still occur. The present study was undertaken to assess the prevalence of anti-hepatitis B core (anti-HBc) positivity and presence of HBV-DNA in serum sample of healthy blood donors negative for both HBsAg and anti-HCV antibody in Shiraz, Iran. Since anti-HBc detection is not mandatory in Iran, we evaluated whether anti-HBc detection could be adopted as a screening assay for safety of donated blood. METHODS: Two thousands serum samples negative for both HBsAg and anti-HCV collected from healthy blood donors were tested for the presence of anti HBc antibody. All samples positive for anti-HBc antibody were then investigated for determination of anti-HBc titre, anti-HBs titre, HbeAg and anti-HBe antibody by enzyme immunoassay (EIA). Every sample that tested negative for HBsAg but positive for anti-HBc alone or in combination with other serological markers was also examined for the presence of HBV-DNA by polymerase chain reaction (PCR). RESULTS: Of the 2000 samples tested, 131 (6.55%) blood samples were found to be positive for anti- HBc. HBV DNA was detected among 16 of 131(12.2%) anti-HBc positive specimens. Further, there was an association between the titration of anti-HBc antibody and the intensity of expected PCR product band. The liver function test results were all in normal range except in 4 of 16 HBV-DNA positive subjects. The mean levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in HBV-PCR positive subjects were 14 IU/l and 23.7 IU/l respectively. INTERPRETATION & CONCLUSION: Anti-HBc antibody should be tested routinely on blood donors volunteers and if the sample found positive regardless of anti-HBs titre, the blood should be discarded. Further testing for HBV-DNA would be appropriate to follow up the donor for HBV infection.